RxDoctor Payments Data

Carolyn Kosack, MD

Cardiovascular Disease · Bloomfield, CTNPI 1659349942

Payments from drug & device makers

$2,046in general payments, 2019–2025

Across 98 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$314
  • Amarin Pharma, Inc.$293
  • Johnson & Johnson$283
  • Boston Scientific$232
  • Esperion Therapeutics, Inc.$187
  • Amgen$143
  • plus $593 from 11 others

What the payments were for

  • Food & beverage$2,046100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,046 in reported general payments places this provider in the 55th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$191,801
Medicare patients
371
Services billed
1,924

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$149,442
XareltoRivaroxaban110$149,148
EntrestoSacubitril/Valsartan15$30,877
JardianceEmpagliflozin11$17,581
VascepaIcosapent Ethyl13$13,978
Praluent PenAlirocumab12$13,923
Metoprolol Succinate477$6,172
Atorvastatin Calcium530$5,794
Icosapent Ethyl12$5,760
Ezetimibe192$3,681
Valsartan176$3,468
Diltiazem 24hr Er (Cd)Diltiazem Hcl105$3,373
Nebivolol Hcl46$3,332
Amlodipine Besylate398$3,034
Rosuvastatin Calcium188$2,597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$283$149,148110 claims
NovartisEntresto$314$30,87715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →